Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited has announced the application for the quotation of 32,909,640 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the issue date set for July 21, 2025. This move is part of a previously announced transaction, which could potentially enhance the company’s market presence and provide additional capital for its ongoing and future projects, thereby impacting its operations and positioning within the biopharmaceutical industry.
More about Immuron Limited
Immuron Limited is a biopharmaceutical company that specializes in the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. The company focuses on leveraging its proprietary technology to create products that target and modulate the immune system within the gastrointestinal tract.
YTD Price Performance: -3.80%
Average Trading Volume: 138,301
Technical Sentiment Signal: Sell
Current Market Cap: A$17.88M
See more insights into IMC stock on TipRanks’ Stock Analysis page.